Evommune, Inc. - 8-K Filing

Evommune announced Phase 2a data for EVO301 in atopic dermatitis will be presented at the European Academy of Dermatology & Venereology Congress. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR · September 23, 2026, 20:06 UTC

Tickers: $EVMN

Read the full article at SEC EDGAR

More Regulatory news

Bitwise Avalanche ETF - 8-K Filing SEC EDGAR · November 12, 2026, 15:06 UTC
MiNK Therapeutics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:05 UTC
Future Vision II Acquisition Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC
THUNDER MOUNTAIN GOLD INC - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC
MiNK Therapeutics, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:49 UTC
SusGlobal Energy Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:42 UTC
Ideal Power Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:25 UTC
DIGI INTERNATIONAL INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:23 UTC
ZeroStack Corp. - 8-K Filing SEC EDGAR · November 12, 2026, 14:22 UTC
Sound Point Meridian Capital, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:22 UTC